A Phase II Trial of SABR (Stereotactic Ablative Body Radiotherapy) for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life and Disease Control Outcomes with 5-Year Minimum Followup

A Phase II Trial of SABR (Stereotactic Ablative Body Radiotherapy) for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life and Disease Control Outcomes with 5-Year Minimum Followup

Purpose/Objective(s): Herein, we report the results of an IRB-approved phase II trial of Varian Trilogy/TrueBeam-based SABR monotherapy for low-risk prostate cancer using the Calypso® System to provide real-time electromagnetic tracking of the prostate’s position during treatment delivery. Material...

Full description

Bibliographic Details
Main Author: Constantine Anastasios Mantz
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-11-01
Series:Frontiers in Oncology
Subjects:
prostate cancer
SBRT
SAbR
stereotactic body radiation therapy
stereotactic ablative radiation therapy
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00279/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00279/full

Similar Items